Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma

ÖZKURT Z. N. , Sucak G. T. , Aki S. Z. , Yagci M., Erdem O.

CUTANEOUS AND OCULAR TOXICOLOGY, cilt.28, sa.3, ss.141-143, 2009 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Konu: 3
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1080/15569520903046934
  • Sayfa Sayıları: ss.141-143


Bortezomib is a potent, selective proteasome inhibitor. It is usually well tolerated, and bortezomib-induced skin lesions are less well known. A 59-year-old man with multiple myeloma underwent autologous hematopoetic stem cell transplantation (AHSCT). Administration of bortezomib was started after AHSCT as his disease progressed despite thalidomide maintenance. He developed a rash afer the third cycle of bortezomib. A biopsy showed superficial and deep perivascular dermatitis. The rash resolved within 4 days; complete response of myeloma was obtained after 8 cycles of bortezomib. The benign clinical course did not require interruption of the treatment, which in turn resulted in complete remission of myeloma.